Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RPT
3001
Rithm Property Trust
RPT
$100M
| $730K | ﹤0.01% |
9,008
+25
| +0.3% | +$2.01K |
|
3002
State Street SPDR Portfolio TIPS ETF
SPIP
$1.01B
| $727K | ﹤0.01% |
23,380
+814
| +4% | +$25.6K |
|
|
ATHX
3003
DELISTED
Athersys, Inc. Common Stock
ATHX
| $726K | ﹤0.01% |
21,812
+2,095
| +11% | +$79.6K |
|
3004
First Internet Bancorp
INBK
$260M
| $723K | ﹤0.01% |
23,162
| – | – |
|
|
EWCZ
3005
DELISTED
European Wax Center
EWCZ
| $722K | ﹤0.01% |
+25,741
| New | +$644K |
|
|
APLT
3006
DELISTED
Applied Therapeutics
APLT
| $720K | ﹤0.01% |
43,336
-317
| -0.7% | -$5.47K |
|
3007
UroGen Pharma
URGN
$2.34B
| $719K | ﹤0.01% |
42,689
+2,174
| +5% | +$34.5K |
|
3008
Park Aerospace
PKE
$817M
| $717K | ﹤0.01% |
52,409
-76,980
| -59% | -$1.13M |
|
|
CCRD
3009
DELISTED
CoreCard
CCRD
| $716K | ﹤0.01% |
17,614
+176
| +1% | +$6.27K |
|
3010
Distribution Solutions Group
DSGR
$1.61B
| $715K | ﹤0.01% |
28,588
+2,006
| +8% | +$52.5K |
|
3011
South Plains Financial
SPFI
$854M
| $714K | ﹤0.01% |
29,263
+2,276
| +8% | +$52.9K |
|
|
BFX
3012
DELISTED
BowFlex Inc.
BFX
| $714K | ﹤0.01% |
76,586
+1,981
| +3% | +$25.4K |
|
|
BNFT
3013
DELISTED
Benefitfocus, Inc.
BNFT
| $714K | ﹤0.01% |
64,308
-131,676
| -67% | -$1.6M |
|
3014
Aterian
ATER
$5.27M
| $712K | ﹤0.01% |
5,478
+1,429
| +35% | +$158K |
|
|
AKUS
3015
DELISTED
Akouos Inc
AKUS
| $710K | ﹤0.01% |
61,102
-50,682
| -45% | -$608K |
|
3016
Superior Group of Companies
SGC
$208M
| $709K | ﹤0.01% |
30,422
+2,198
| +8% | +$51.7K |
|
3017
Stereotaxis
STXS
$137M
| $707K | ﹤0.01% |
131,290
+3,367
| +3% | +$25.4K |
|
3018
Tenaya Therapeutics
TNYA
$173M
| $707K | ﹤0.01% |
+34,211
| New | +$735K |
|
3019
CuriosityStream
CURI
$162M
| $706K | ﹤0.01% |
66,979
+3,714
| +6% | +$43.7K |
|
3020
TherapeuticsMD
TXMD
$24.4M
| $706K | ﹤0.01% |
19,021
-30,758
| -62% | -$1.37M |
|
3021
Janux Therapeutics
JANX
$1.02B
| $705K | ﹤0.01% |
+32,576
| New | +$937K |
|
|
TAST
3022
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $705K | ﹤0.01% |
192,432
-167,829
| -47% | -$749K |
|
3023
Eterna Therapeutics
ERNA
$5.31M
| $701K | ﹤0.01% |
10
+2
| +25% | +$173K |
|
|
FNCH
3024
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
| $697K | ﹤0.01% |
1,786
+140
| +9% | +$59.7K |
|
3025
Foghorn Therapeutics
FHTX
$403M
| $696K | ﹤0.01% |
49,958
-21,403
| -30% | -$237K |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.